Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction (CPHIT-HFpEF)
2026年7月12日 更新者：Tang Yida、Peking University Third Hospital
Cardiovascular-Kidney-Metabolic (CKM) Syndrome is a continuous clinical disease spectrum integrating cardiovascular, renal, and metabolic disorders. Heart failure with preserved ejection fraction (HFpEF) is considered Stage 4 of CKM syndrome, characterized primarily by impairment of cardiac structure and function. Numerous studies have confirmed that exercise intervention is effective in improving metabolic profiles and inflammatory status in Stages 0-3 of CKM syndrome (e.g., obesity, metabolic syndrome, hypertension, and diabetes), and significantly improves clinical outcomes. However, for Stage 4 CKM syndrome, especially in patients with HFpEF, conventional exercise prescription faces significant challenges in balancing safety and efficacy. Moreover, traditional "one-size-fits-all" exercise rehabilitation strategies have failed to significantly improve clinical outcomes due to the lack of individualized precision approaches.
To address this gap, this study proposes to adopt a multicenter, randomized, controlled design, enrolling patients with HFpEF at Stage 4 of CKM syndrome and randomly assigning them to either a personalized high-intensity interval training (HIIT) intervention group or a standard care control group. The **primary endpoint** of this study is the change in peak oxygen consumption (peak VO₂) from baseline after 24 weeks of intervention. In addition, a series of **secondary endpoints** have been established for comprehensive evaluation, including inflammatory biomarkers, cardiac structure and function, quality of life, and composite clinical events. These endpoints aim to comprehensively assess the intervention effects from the perspectives of cardiopulmonary function, metabolism and inflammation, quality of life, and clinical outcomes, as well as to explore the underlying mechanisms.
This study is expected to validate the beneficial effects of personalized exercise on peak VO₂ and various secondary endpoints in patients with Stage 4 CKM syndrome. It will not only provide high-level evidence-based support for exercise therapy in HFpEF but also deepen the understanding of the role of exercise intervention in the full-course management of CKM syndrome, offering key scientific support for the development of precision prevention and treatment strategies across all stages.
調査の概要
状態
状態
まだ募集していません
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
介入
入学 (推定)
入学
192
段階
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
研究連絡先
- 名前：Yida Tang, MD,PhD
- 電話番号：010-82265996
- メール：tangyida@bjmu.edu.cn
研究場所
-
-
-
Beijing、中国
- Peking University First Hospital
-
主任研究者：
- Jianping Li
-
Beijing、中国
- Peking University Third Hospital
-
コンタクト：
- Yida Tang
- 電話番号：010-82265996
- メール：tangyida@bjmu.edu.cn
-
Beijing、中国
- Beijing Hospital
-
主任研究者：
- Fang Wang
-
Beijing、中国
- Peking University People's Hospital
-
主任研究者：
- Jian Liu
-
Beijing、中国
- Beijing Chao-Yang Hospital, Capital Medical University
-
主任研究者：
- Yuanhua Yang
-
Beijing、中国
- Beijing Zhongguancun Hospital
-
主任研究者：
- Chaoyi Zhang
-
Beijing、中国
- Beijing Xiaotangshan Hospital
-
主任研究者：
- Rong Guo
-
Beijing、中国
- Community Health Station of the Party School of the Central Committee of C.P.C
-
主任研究者：
- Wei Zhao
-
Beijing、中国
- Jimenli Community Health Service Center
-
主任研究者：
- Qiue Zhang
-
Beijing、中国
- Xueyuanlu Community Health Service Center
-
主任研究者：
- Hongyun Chi
-
Shanghai、中国
- Shanghai East Hospital
-
主任研究者：
- Ying Li
-
Wuhan、中国
- Wuhan Asia Heart Hospital
-
主任研究者：
- Yin Li
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Men and women aged 35-70 years;
Physical inactivity / sedentary lifestyle defined as:
Sedentary behavior: average daily sitting time > 6 hours over the past 6 months; AND/OR Insufficient physical activity: average weekly moderate-intensity physical activity < 150 minutes or vigorous-intensity physical activity < 75 minutes as assessed by the International Physical Activity Questionnaire (IPAQ);
- Patients with HFpEF at Stage 4 of CKM syndrome who have been clinically stable within the past month (New York Heart Association [NYHA] functional class II-III);
- Willingness to improve health status through appropriate exercise.
Exclusion Criteria:
- Presence of contraindications to cardiopulmonary exercise testing (CPET);
- Positive findings on the exercise electrocardiogram (ECG) during CPET;
- Diagnosis of psychiatric disorders;
- Presence of movement disorders or lower extremity exercise-related injuries within the past 6 months;
- Women who are pregnant, breastfeeding, or planning to become pregnant in the near future;
- Other conditions deemed unsuitable for participation in this study by the investigators;
- Refusal to sign the informed consent form.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
アーム数
2
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：HIIT intervention group
Subjects in the intervention group will undergo a 24-week personalized high-intensity interval training (HIIT) program, four times per week, with the exercise protocol tailored based on cardiopulmonary exercise testing (CPET).
In addition, they will receive guideline-directed healthy lifestyle recommendations and optimal medical therapy (GDMT)
|
Subjects in the intervention group will receive a personalized high-intensity interval training (HIIT) protocol based on cardiopulmonary exercise testing (CPET) and will undergo a 24-week HIIT intervention, four times per week.The exercise protocol consisted of a 5-minute warm-up at 30-40 watts, followed by 8 cycles of high-intensity exercise performed at 80-90% of peak VO₂ for 30 seconds, each interspersed with a 60-second active recovery period of low-intensity exercise at 50-60% of peak VO₂ , and concluded with a 5-minute cool-down at 30-40 watts.
|
|
介入なし：Standard care control group
Control group subjects will receive guideline-directed optimal medical therapy (GDMT) , identical to that provided to the intervention group.
In addition, they will receive a single, standardized health education session focused on HFpEF and obesity management, covering general recommendations regarding diet, weight management, and regular physical activity.
No structured or supervised exercise prescription or program will be offered to the control group.
|
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Peak VO2
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Peak VO2 is assessed through CPET, using a maximal graded treadmill test based on the Chinese expert consensus on the standardized clinical application of CPET.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Blood specimen
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Lab tests include cytokines
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Blood specimen
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Lab tests include high-sensitivity C-reactive protein (hs-CRP)
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Blood specimen
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Lab tests include N-terminal pro-B-type natriuretic peptide (NT-proBNP)
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered, disease-specific instrument that assesses physical limitations, symptoms (frequency, severity, and change), self-efficacy, social function, and quality of life in patients with heart failure.
It has demonstrated high reliability and validity.
Scores are transformed to a range of 0 to 100, with higher scores reflecting better health-related quality of life.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
The New York Heart Association (NYHA) Functional Classification
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
The New York Heart Association (NYHA) Functional Classification is a commonly used tool by clinicians to quantify the severity of symptoms and physical activity limitations in patients with heart failure.
The classification places patients into one of four categories: Class I (no limitation of physical activity), Class II (slight limitation, ordinary activity causes symptoms), Class III (marked limitation, less than ordinary activity causes symptoms), and Class IV (unable to carry on any physical activity without discomfort, symptoms may be present at rest).
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Montreal Cognitive Assessment (MoCA)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
The Montreal Cognitive Assessment (MoCA) is a standardized 30-point screening tool used to detect cognitive impairment.
It assesses multiple cognitive domains including visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation.
The test takes approximately 10 minutes to administer.
Scores range from 0 to 30, with higher scores reflecting better cognitive function.
A score of 26 or above is generally considered normal; 18-25 indicates mild cognitive impairment; 10-17 indicates moderate cognitive impairment; and below 10 indicates severe cognitive impairment.
One point is added to the raw score for individuals with 12 or fewer years of education.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Hospital Anxiety and Depression Scale (HADS)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
The Hospital Anxiety and Depression Scale (HADS) is a 14-item, self-administered screening tool designed to assess symptoms of anxiety and depression.
It comprises two independent subscales: anxiety (HADS-A) and depression (HADS-D), each containing 7 items.
Each item is scored from 0 to 3, yielding a subscale total score ranging from 0 to 21, with higher scores indicating greater symptom severity.
Based on established cutoffs, scores of 0-7 are considered normal, 8-10 indicate borderline abnormal (mild), and 11-21 indicate abnormal (moderate to severe).
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Pittsburgh Sleep Quality Index (PSQI)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item, self-rated questionnaire that assesses sleep quality over a 1-month time interval.
It comprises seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
Each component is scored from 0 to 3, and the sum of these seven components yields a global PSQI score ranging from 0 to 21, with higher scores indicating poorer sleep quality.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
International Physical Activity Questionnaire (IPAQ)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
The International Physical Activity Questionnaire (IPAQ) Long Form is a 27-item, self-administered questionnaire that assesses physical activity over the past 7 days across five life domains: work-related activity, transportation-related activity, domestic and gardening activity, leisure-time activity, and sitting time.
Metabolic equivalent (MET) values assigned are: walking = 3.3 METs, moderate-intensity activity = 4.0 METs, and vigorous-intensity activity = 8.0 METs.
Activity volume for each domain is calculated as MET-minutes per week (MET-min/week) using the formula: MET value × days per week × minutes per day.
Total physical activity is derived by summing MET-min/week across all domains.
Based on total MET-min/week, participants are classified into three levels: low (< 600 MET-min/week), moderate (600-3000 MET-min/week), and high (≥ 3000 MET-min/week)
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Peak O₂ pulse
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Peak O₂ pulse will be assessed by cardiopulmonary exercise testing (CPET) .
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Anaerobic Threshold (AT)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Anaerobic Threshold (AT) will be assessed by cardiopulmonary exercise testing (CPET) .
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
VE/VCO₂ slope
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
VE/VCO₂ slope will be assessed by cardiopulmonary exercise testing (CPET) .
Ventilation (VE) and carbon dioxide output (VCO₂) will be measured breath-by-breath throughout the test.
The VE/VCO₂ slope will be calculated by linear regression analysis of VE versus VCO₂ using data from the beginning of exercise up to the respiratory compensation point (RCP).
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
left atrial volume index (LAVI) assessed by echocardiography
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left atrial volume index (LAVI) will be assessed using echocardiography.
LAVI is calculated as left atrial volume indexed to body surface area (BSA), and will be reported in mL/m².
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
left atrial volume index (LAVI) assessed by cardiac magnetic resonance(CMR)
時間枠：Baseline（week 0），End of study（week 24 ）
|
Left atrial volume index (LAVI) will be measured by cardiac magnetic resonance(CMR).
LAVI is calculated as left atrial volume indexed to body surface area (BSA) and reported in mL/m².
|
Baseline（week 0），End of study（week 24 ）
|
|
Left ventricular mass index (LVMI) assessed by echocardiography
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left ventricular mass index (LVMI) will be measured by echocardiography.
LVMI is derived by indexing LVM to body surface area (BSA) and reported in g/m².
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Left ventricular mass index (LVMI) assessed by cardiac magnetic resonance(CMR)
時間枠：Baseline（week 0），End of study（week 24）
|
Left ventricular mass index (LVMI) will be measured by cardiac magnetic resonance(CMR).
LVMI is derived by indexing LVM to body surface area (BSA) and reported in g/m².
|
Baseline（week 0），End of study（week 24）
|
|
left atrial volume (LAV)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left atrial volume (LAV) will be assessed using echocardiography , and will be reported in mL.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
left atrial area (LAA)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left atrial area (LAA) will be measured by echocardiography .
Left atrial area index (LAAI) will be calculated as LAA max divided by body surface area (BSA) and reported in cm²/m².
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
left atrial diameter (LAD)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left atrial diameter (LAD) will be measured by echocardiography and reported in mm.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Diastolic function index (E/e' ratio)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Diastolic function index (E/e' ratio) will be measured by echocardiography.
The E/e' ratio is a noninvasive surrogate marker for estimating left ventricular filling pressure and is central to the grading of diastolic dysfunction.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Global longitudinal strain (GLS)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Global longitudinal strain (GLS) will be measured by echocardiography and reported in %.
GLS is expressed as a negative value, with more negative values indicating better left ventricular systolic function.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Left ventricular myocardial work (MW)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left ventricular myocardial work (MW) will be assessed by echocardiography and reported in mmHg%.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Left atrial strain (LAS)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Left atrial strain (LAS) will be measured by echocardiography and reported in %.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Epicardial adipose tissue volume (EATV)
時間枠：Baseline（week 0），End of study（week 24 ）
|
Epicardial adipose tissue volume (EATV) will be quantified using cardiac magnetic resonance (CMR) and reported in mL.
|
Baseline（week 0），End of study（week 24 ）
|
|
Pericardial adipose tissue volume
時間枠：Baseline（week 0），End of study（week 24 ）
|
Pericardial adipose tissue volume will be quantified using cardiac magnetic resonance (CMR) and reported in mL
|
Baseline（week 0），End of study（week 24 ）
|
|
Liver fat content (LFC)
時間枠：Baseline（week 0），End of study（week 24 ）
|
Liver fat content (LFC) will be quantified using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and expressed as a percentage (%)
|
Baseline（week 0），End of study（week 24 ）
|
|
Liver Stiffness Measurement（LSM）assessed by magnetic resonance elastography (MRE)
時間枠：Baseline（week 0），End of study（week 24 ）
|
Liver stiffness measurement (LSM) will be assessed by magnetic resonance elastography (MRE) and reported in kilopascals (kPa), with higher values indicating more severe liver fibrosis
|
Baseline（week 0），End of study（week 24 ）
|
|
Visceral adipose tissue area (VATA)
時間枠：Baseline（week 0），End of study（week 24 ）
|
Visceral adipose tissue area (VATA) will be measured using non-contrast chest CT and reported in cm²
|
Baseline（week 0），End of study（week 24 ）
|
|
BMI
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Weight (kg) is measured with digital weighing scale.
Height (cm) is measured with a portable stadiometer.
BMI is calculated as weight in kilograms divided by the square of height in meters
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Waist-to-height ratio (WHtR)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Waist-to-height ratio (WHtR) will be calculated using standard anthropometric measurements.
Waist circumference will be measured at the midpoint between the lower costal margin and the iliac crest at the mid-axillary line at the end of expiration.
WHtR is calculated as waist circumference divided by height.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Waist-to-hip ratio (WHR)
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Waist-to-hip ratio (WHR) will be calculated using standard anthropometric measurements.
Waist circumference will be measured at the midpoint between the lower costal margin and the iliac crest at the mid-axillary line at the end of expiration; hip circumference will be measured at the maximal gluteal protuberance.
WHR as waist circumference divided by hip circumference.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
All-Cause Death
時間枠：Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
All-cause death is defined as death from any cause occurring from baseline to the end of follow-up.
Death information will be ascertained through regular follow-up, medical record review, and family reports.
For participants lost to follow-up, vital status will be confirmed by cross-referencing with the local population death registry.
This study will report the incidence of all-cause death from randomization to the end of study.
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
|
Heart failure rehospitalization
時間枠：Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
Heart failure rehospitalization is defined as an unplanned hospitalization (≥24 hours) due to decompensated heart failure, requiring at least one of the following intravenous therapies during the hospital stay: (1) intravenous diuretics; (2) intravenous vasodilators; or (3) intravenous inotropic agents.
This study will report the incidence of heart failure rehospitalization from baseline to the end of the study.
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
|
Exercise intervention-related adverse events
時間枠：Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
Exercise intervention-related adverse events are defined as any adverse medical events occurring during participation in the exercise intervention protocol or within post-exercise, judged by the investigator to have a possible, probable, or definite causal relationship with the study exercise intervention.
These include, but are not limited to, exercise-induced arrhythmias, angina, hypotensive/hypertensive crises, and musculoskeletal injuries requiring medical intervention.
The overall incidence of exercise-related adverse events will be reported from baseline to the end of the study.
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
|
Clinical deterioration
時間枠：Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
Clinical deterioration is defined as any of the following events due to worsening heart failure that do not meet hospitalization criteria: (1) unscheduled clinic visit for worsening HF symptoms (dyspnea, edema, fatigue) requiring therapy intensification; (2) emergency department observation (<24 hours) for decompensated HF; (3) outpatient/day-care intravenous diuretics or vasodilators; or (4) significant upward titration of oral diuretics (e.g., dose doubling or new agent), confirmed by the investigator.
Events progressing to hospitalization will be captured under "HF rehospitalization" and excluded here.
Incidence will be reported as proportion of participants from baseline to the end of the study.
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
|
|
Blood specimen
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Lab tests include adipokines
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Blood specimen
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Lab tests include cardiac troponin
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Liver Stiffness Measurement（LSM）assessed by FibroTouch transient elastography
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Liver stiffness measurement (LSM) will be assessed using the FibroTouch transient elastography system and reported in kilopascals (kPa).
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
|
Fecal specimens
時間枠：Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
Fecal specimens will be collected at baseline and Week 24 for gut microbiome profiling.
|
Baseline（week 0），Mid-term（week 12），End of study（week 24 ）
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
協力者
協力者
捜査官
捜査官
- スタディチェア：Yida Tang, MD,PhD、Peking University Third Hospital
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
研究開始
2026年7月1日
一次修了 (推定)
一次修了
2027年7月1日
研究の完了 (推定)
研究の完了
2028年4月30日
試験登録日
最初に提出
最初に提出
2026年6月21日
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
2026年7月3日
最初の投稿 (実際)
最初の投稿
2026年7月9日
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
2026年7月14日
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
2026年7月12日
最終確認日
最終確認日
2026年7月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CPHIT-2
- BRWEP2024W014090204 (その他の助成金/資金番号：Beijing Municipal Health Commission)
- 2025ZD0546100 (その他の助成金/資金番号：National Health Commission of the People's Republic of China)
- TY2025008 (その他の助成金/資金番号：Peking University-Golden Resource"Tengyun Clinical Research Program")
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。